142 related articles for article (PubMed ID: 37903564)
21. Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective.
Kim BJ; Day RW; Davis CH; Narula N; Kroll MH; Tzeng CWD; Aloia TA
J Thromb Haemost; 2017 Nov; 15(11):2158-2164. PubMed ID: 28846822
[TBL] [Abstract][Full Text] [Related]
22. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
23. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective.
Trepanier M; Alhassan N; Sabapathy CA; Liberman AS; Charlebois P; Stein BL; S Feldman L; Lee L
Dis Colon Rectum; 2019 Nov; 62(11):1381-1389. PubMed ID: 31318768
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
26. Utilization of Minimally Invasive Surgery in Endometrial Cancer Care: A Quality and Cost Disparity.
Fader AN; Weise RM; Sinno AK; Tanner EJ; Borah BJ; Moriarty JP; Bristow RE; Makary MA; Pronovost PJ; Hutfless S; Dowdy SC
Obstet Gynecol; 2016 Jan; 127(1):91-100. PubMed ID: 26646127
[TBL] [Abstract][Full Text] [Related]
27. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
31. Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. A Danish National Cohort Study.
Kahr HS; Christiansen OB; Høgdall C; Grove A; Mortensen RN; Torp-Pedersen C; Knudsen A; Thorlacius-Ussing O
Gynecol Oncol; 2019 Oct; 155(1):112-118. PubMed ID: 31378374
[TBL] [Abstract][Full Text] [Related]
32. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT
Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study.
Kuroda S; Kikuchi S; Kakiuchi Y; Watanabe M; Kuwada K; Tsumura T; Nishizaki M; Kagawa S; Hinotsu S; Fujiwara T
Int J Surg; 2021 May; 89():105946. PubMed ID: 33892160
[TBL] [Abstract][Full Text] [Related]
35. Disparities in Surgical Care Among Women With Endometrial Cancer.
Mannschreck D; Matsuno RK; Moriarty JP; Borah BJ; Dowdy SC; Tanner EJ; Makary MA; Stone RL; Levinson KL; Temkin SM; Fader AN
Obstet Gynecol; 2016 Sep; 128(3):526-34. PubMed ID: 27500330
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
37. A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting.
Bao Y; Zhao G; Qu S; Xiong T; Yao X; Wu B
Clin Drug Investig; 2020 Feb; 40(2):161-171. PubMed ID: 31773492
[TBL] [Abstract][Full Text] [Related]
38. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
[TBL] [Abstract][Full Text] [Related]
39. Patient cost associated with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer.
Cain K; Schmeler KM; Langley G; Max O; Ramirez PT; Levenback CF
Gynecol Oncol; 2012 Oct; 127(1):18-21. PubMed ID: 22813886
[TBL] [Abstract][Full Text] [Related]
40. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
